All In Biotech

Drug Trial Radar · NCT05125068

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy

Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

24

Actual

Start

Mar 21, 2022

Primary completion

Jul 31, 2023

Study completion Jul 31, 2023

Sponsor

Lead sponsor
Eledon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

Conditions

  • IgA Nephropathy
  • IgAN

Interventions

  • AT-1501Drug

    AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy - change in participants UPCRTime frame: Up to 24 weeks
  2. Safety- Number of participants with treatment related adverse eventsTime frame: Through study completion, an average of 100 weeks

Locations

26 sites in 10 countries. Site status is shown where the registry gives one.

  • Liverpool Hospital

    Liverpool, South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Western Health

    St Albans, Victoria, Australia

  • University Hospital Centre Sisters of Charity

    Zagreb, Croatia

  • University Hospital Dubrava Zagreb

    Zagreb, Croatia

  • University Malaya Medical Centre (UMMC)

    Kuala Lumpur, Kuala Lumpur WP, Malaysia

  • Hospital Tengku Ampuan Afzan (HTAA)

    Kuantan, Pahang, Malaysia

  • Hospital Queen Elizabeth

    Kota Kinabalu, Sabah, Malaysia

  • Hospital Kajang

    Kajang, Selangor, Malaysia

  • Hospital Serdang

    Kajang, Selangor, Malaysia

  • Waikato Hospital

    Hamilton, New Zealand

  • Hawke's Bay Hospital

    Hastings, New Zealand

  • University of Santo Tomas Hospital

    Sampaloc, Manila, Philippines

  • Medical University of Bialystok UI

    Bialystok, Poland

  • Specjalistyczne Centrum Medyczne, SCM Spółka

    Krakow, Poland

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Virgen de la Macarena

    Seville, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Hospital de Sagunto

    Sagunto, Valencia, Spain

  • National Hospital of Sri Lanka

    Colombo, Sri Lanka

  • Sri Jayawardanepura General Hospital

    Nugegoda, Sri Lanka

  • Phramongkutklao Hospital

    Bangkok, Thailand

  • Chiang Mai University

    Chiang Mai, Thailand

  • Prince of Songkla University

    Dusit, Bangkok, Thailand

  • Chulalongkorn University

    Pathum Wan, Bangkok, Thailand

  • Kings College Hospital

    Camberwell, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.